1. Home
  2. GILD
  3. GILD News

Latest Gilead Sciences Inc. (GILD) News on October 18, 2024

GILD

MT Newswires

12 hours ago

BMO Capital Adjusts Price Target on Gilead Sciences to $94 From $85

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
GILD

Zacks

13 hours ago

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
GILD

Zacks

2 days ago

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts

How Brookfield Infrastructure, Invitation Homes And Gilead Sciences Can Put Cash In Your Pocket
GILD

Benzinga

4 days ago

How Brookfield Infrastructure, Invitation Homes And Gilead Sciences Can Put Cash In Your Pocket

Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
GILD

Zacks

7 days ago

Gilead's HIV Prevention Treatment Lenacapavir Shows Potential

GILD

MT Newswires

7 days ago

Morgan Stanley Adjusts Price Target on Gilead Sciences to $84 From $79

Is Gilead Sciences, Inc. (NASDAQ:GILD) The Most Popular Stock Among Mutual Funds According To Goldman Sachs?
GILD

Insider Monkey

7 days ago

Is Gilead Sciences, Inc. (NASDAQ:GILD) The Most Popular Stock Among Mutual Funds According To Goldman Sachs?

Gilead Sciences Inc (GILD) Q2 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ...
GILD

GuruFocus.com

8 days ago

Gilead Sciences Inc (GILD) Q2 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ...

Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
GILD

Business Wire

8 days ago

Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

GILD

MT Newswires

8 days ago

Raymond James Adjusts Gilead Sciences Price Target to $95 From $94

GILD

MT Newswires

8 days ago

JPMorgan Adjusts Price Target on Gilead Sciences to $100 From $95, Maintains Overweight Rating

Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
GILD

Business Wire

9 days ago

Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know
GILD

Zacks

9 days ago

Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
GILD

Business Wire

10 days ago

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference

GILD

MT Newswires

11 days ago

Wells Fargo Upgrades Gilead Sciences to Overweight From Equalweight, Adjusts PT to $100 From $78

AstraZeneca and Gilead Sciences merger would be the biggest in the pharma history
GILD

Pharmaceutical Technology

11 days ago

AstraZeneca and Gilead Sciences merger would be the biggest in the pharma history

Gilead Sciences' (NASDAQ:GILD) investors will be pleased with their favorable 62% return over the last five years
GILD

Simply Wall St.

13 days ago

Gilead Sciences' (NASDAQ:GILD) investors will be pleased with their favorable 62% return over the last five years

Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?
GILD

Zacks

14 days ago

Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?

GILD

MT Newswires

14 days ago

Goldman Sachs Adjusts Price Target on Gilead Sciences to $74 From $71

GILD

MT Newswires

14 days ago

Barclays Adjusts Price Target on Gilead Sciences to $84 From $76, Maintains Equalweight Rating

GILD

MT Newswires

14 days ago

RBC Lifts Price Target on Gilead Sciences to $75 From $74, Keeps Sector Perform Rating

GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
GILD

Zacks

14 days ago

GILD Grants Right for HIV PrEP Candidate to Six Generic Companies

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
GILD

Zacks

15 days ago

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

GILD

MT Newswires

15 days ago

Redburn Atlantic Adjusts Price Target on Gilead Sciences to $123 From $119, Maintains Buy Rating

Gilead signs agreements to facilitate access to HIV prevention drug
GILD

Pharmaceutical Technology

15 days ago

Gilead signs agreements to facilitate access to HIV prevention drug

Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
GILD

PR Newswire

15 days ago

Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries

GILD

MT Newswires

16 days ago

Gilead Sciences Signs Licensing Deals With 6 Drugmakers to Manufacture HIV Prevention Drug Lenacapavir

Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
GILD

Business Wire

16 days ago

Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries

Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
GILD

Zacks

16 days ago

Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know

Championing HIV Services for LGBTQ+ Youth
GILD

ACCESSWIRE

23 days ago

Championing HIV Services for LGBTQ+ Youth

Gilead Sciences (GILD) Stock Slides as Market Rises: Facts to Know Before You Trade
GILD

Zacks

23 days ago

Gilead Sciences (GILD) Stock Slides as Market Rises: Facts to Know Before You Trade

AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
GILD

Investor's Business Daily

24 days ago

AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug

Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
GILD

Benzinga

24 days ago

Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles

AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
GILD

Investor's Business Daily

25 days ago

AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug

Gilead Sciences, Verizon Communications And ManpowerGroup Are Winners For Passive Income
GILD

Benzinga

a month ago

Gilead Sciences, Verizon Communications And ManpowerGroup Are Winners For Passive Income

3 Dirt Cheap Stocks to Buy Right Now
GILD

Motley Fool

a month ago

3 Dirt Cheap Stocks to Buy Right Now

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
GILD

Zacks

a month ago

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

High Growth Tech Stocks To Watch This September 2024
GILD

Simply Wall St.

a month ago

High Growth Tech Stocks To Watch This September 2024

Working to Build Next-Generation Cancer Therapies
GILD

ACCESSWIRE

a month ago

Working to Build Next-Generation Cancer Therapies

Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
GILD

Zacks

a month ago

Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why

This 'forgotten child' is one of the best biotech plays: Analyst
GILD

Yahoo Finance Video

a month ago

This 'forgotten child' is one of the best biotech plays: Analyst

GILD

MT Newswires

a month ago

Gilead Sciences Insider Sold Shares Worth $1,795,287, According to a Recent SEC Filing

Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
GILD

Clinical Trials Arena

a month ago

Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir

Should You Be Worried About Gilead Sciences, Inc.'s (NASDAQ:GILD) 5.7% Return On Equity?
GILD

Simply Wall St.

a month ago

Should You Be Worried About Gilead Sciences, Inc.'s (NASDAQ:GILD) 5.7% Return On Equity?

Got $200? 2 Healthcare Stocks to Buy and Hold Forever
GILD

Motley Fool

a month ago

Got $200? 2 Healthcare Stocks to Buy and Hold Forever

Insider Sale: Johanna Mercier Sells 29,357 Shares of Gilead Sciences Inc (GILD)
GILD

GuruFocus.com

a month ago

Insider Sale: Johanna Mercier Sells 29,357 Shares of Gilead Sciences Inc (GILD)

GILD

MT Newswires

a month ago

Gilead Sciences Insider Sold Shares Worth $2,459,577, According to a Recent SEC Filing

Gilead Stock Rises as HIV Prevention Injection Meets Study Goals
GILD

Zacks

a month ago

Gilead Stock Rises as HIV Prevention Injection Meets Study Goals

Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial
GILD

BioPharma Dive

a month ago

Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial

Why Gilead Sciences Stock Thrashed the Market Today
GILD

Motley Fool

a month ago

Why Gilead Sciences Stock Thrashed the Market Today

Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention
GILD

Investor's Business Daily

a month ago

Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention

Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
GILD

Benzinga

a month ago

Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections

Gilead Stock Rises on Positive Study Results for Twice-Yearly HIV Drug
GILD

The Wall Street Journal

a month ago

Gilead Stock Rises on Positive Study Results for Twice-Yearly HIV Drug

GILD

Investing.com

a month ago

Gilead says HIV prevention injection reduced cases by 96%, sending shares higher

Helping End HIV - Gilead Sciences
GILD

ACCESSWIRE

a month ago

Helping End HIV - Gilead Sciences

GILD

MT Newswires

a month ago

Gilead Sciences Says Twice-Yearly HIV Treatment Lenacapavir Reduces Infections by 96%

Gilead Unveils More Positive Data on HIV Prevention Shot
GILD

Barrons.com

a month ago

Gilead Unveils More Positive Data on HIV Prevention Shot

Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
GILD

Business Wire

a month ago

Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
GILD

Zacks

a month ago

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

GILD

MT Newswires

a month ago

Raymond James Raises Gilead Sciences' Price Target to $94 From $93, Outperform Rating Maintained

Gilead and Genesis partner to create novel therapies using AI
GILD

Pharmaceutical Technology

a month ago

Gilead and Genesis partner to create novel therapies using AI

Seramount Ranks Gilead Sciences Among Its Leading Inclusion Index Company
GILD

ACCESSWIRE

a month ago

Seramount Ranks Gilead Sciences Among Its Leading Inclusion Index Company

GILD

MT Newswires

a month ago

Gilead Sciences, Genesis Therapeutics Sign Deal to Discover, Develop Novel Therapies

Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
GILD

Business Wire

a month ago

Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies

Gilead Sciences, Inc. (GILD): Are Hedge Funds Bullish On This Biotech Stock?
GILD

Insider Monkey

a month ago

Gilead Sciences, Inc. (GILD): Are Hedge Funds Bullish On This Biotech Stock?

Gilead Sciences: Living With a Rare Liver Disease: Maria's Journey
GILD

ACCESSWIRE

a month ago

Gilead Sciences: Living With a Rare Liver Disease: Maria's Journey

Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
GILD

Business Wire

a month ago

Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer

Gilead Sciences: Innovative Approaches to Healthcare Can Remove Barriers
GILD

ACCESSWIRE

a month ago

Gilead Sciences: Innovative Approaches to Healthcare Can Remove Barriers

GILD

MT Newswires

a month ago

RBC Raises Price Target on Gilead Sciences to $74 From $72, Keeps Sector Perform Rating

Avenzo and Gilead partner for breast cancer combination regimen trial
GILD

Clinical Trials Arena

a month ago

Avenzo and Gilead partner for breast cancer combination regimen trial

Gilead Sciences, Inc. (NASDAQ:GILD) is favoured by institutional owners who hold 86% of the company
GILD

Simply Wall St.

2 months ago

Gilead Sciences, Inc. (NASDAQ:GILD) is favoured by institutional owners who hold 86% of the company

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.
GILD

Barrons.com

2 months ago

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.

How Gilead Sciences, Virtus Investment And Hess Midstream Could Put Cash In Your Pocket
GILD

Benzinga

2 months ago

How Gilead Sciences, Virtus Investment And Hess Midstream Could Put Cash In Your Pocket

GILD

Argus Research

2 months ago

The Argus High-Yield Model Portfolio

Insider Sale: Johanna Mercier Sells 9,513 Shares of Gilead Sciences Inc (GILD)
GILD

GuruFocus.com

2 months ago

Insider Sale: Johanna Mercier Sells 9,513 Shares of Gilead Sciences Inc (GILD)

GILD

MT Newswires

2 months ago

Gilead Sciences Insider Sold Shares Worth $742,299, According to a Recent SEC Filing

Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday
GILD

Investopedia

2 months ago

Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday

GILD

MT Newswires

2 months ago

Jefferies Adjusts Price Target on Gilead Sciences to $95 From $90, Maintains Buy Rating

“The Adventure Jar,” Showcases a Family Navigating the Challenges of a Cancer Diagnosis and Finding Magic in Time Together
GILD

ACCESSWIRE

2 months ago

“The Adventure Jar,” Showcases a Family Navigating the Challenges of a Cancer Diagnosis and Finding Magic in Time Together

Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?
GILD

Zacks

2 months ago

Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?

GILD

Argus Research

2 months ago

Analyst Report: Gilead Sciences, Inc.

GILD

Argus Research

2 months ago

Market Update: CMS, GILD, INTU, PRGO, TJX, PTON

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
GILD

Zacks

2 months ago

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Gilead Sciences to Present at Upcoming Investor Conferences
GILD

Business Wire

2 months ago

Gilead Sciences to Present at Upcoming Investor Conferences

Exploring Three High Growth Tech Stocks in the United States
GILD

Simply Wall St.

2 months ago

Exploring Three High Growth Tech Stocks in the United States

How To Earn $100 Per Month From Gilead Sciences Stock
GILD

Benzinga

2 months ago

How To Earn $100 Per Month From Gilead Sciences Stock

Gilead Sciences: "One of Best Employers for Women" by Forbes
GILD

ACCESSWIRE

2 months ago

Gilead Sciences: "One of Best Employers for Women" by Forbes

Building a Bridge to a Healthier World for Youth in Africa with Gilead Sciences
GILD

ACCESSWIRE

2 months ago

Building a Bridge to a Healthier World for Youth in Africa with Gilead Sciences

Gilead partners with PANTHERx for LIVDELZI distribution
GILD

Pharmaceutical Technology

2 months ago

Gilead partners with PANTHERx for LIVDELZI distribution

Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi
GILD

Zacks

2 months ago

Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi

GILD

MT Newswires

2 months ago

Gilead Sciences Collaborates With PANTHERx Rare for Livdelzi Distribution

Gilead’s PBC therapy Livdelzi bags accelerated approval
GILD

Pharmaceutical Technology

2 months ago

Gilead’s PBC therapy Livdelzi bags accelerated approval

FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal
GILD

Benzinga

2 months ago

FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal

GILD

MT Newswires

2 months ago

Truist Securities Adjusts Price Target on Gilead Sciences to $83 From $82, Maintains Hold Rating

GILD

BioPharma Dive

2 months ago

FDA clears Gilead drug acquired in $4.3B buyout

GILD

MT Newswires

2 months ago

Truist Adjusts Price Target on Gilead Sciences to $83 From $82, Maintains Hold Rating

Insider Sale: Johanna Mercier Sells 5,490 Shares of Gilead Sciences Inc (GILD)
GILD

GuruFocus.com

2 months ago

Insider Sale: Johanna Mercier Sells 5,490 Shares of Gilead Sciences Inc (GILD)

GILD

MT Newswires

2 months ago

Gilead Sciences Gets US FDA's Accelerated Approval for Livdelzi

GILD

MT Newswires

2 months ago

Gilead Sciences Insider Sold Shares Worth $406,150, According to a Recent SEC Filing

Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
GILD

Business Wire

2 months ago

Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Share on Social Networks: